__

Power 3 Medical Products Inc. (OTC BB: PWRM) recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE: PFE), Exelon (Rivastigmine, Novartis – NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene. PWRM’s NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, PWRM’s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms

DG FastChannel®, Inc. (NASDAQ: DGIT) reported that it will report its second quarter financial results before the market opens on Wednesday, August 4, 2010. The Company will host a conference call and webcast at 10:00 a.m. ET that morning to review the results.

Highwoods Properties (NYSE: HIW) Board of Directors declared a cash dividend of $0.425 per share of common stock for the quarter ended June 30, 2010, which equates to an annual dividend of $1.70 per share and is payable on September 8, 2010 to shareholders of record as of August 16, 2010.

RSC Holdings Inc. (NYSE: RRR), one of the largest equipment rental providers in North America, reported financial results for the quarter ended June 30, 2010. Total revenue was $301 million and rental revenue was $260 million, compared with $327 million and $271 million, respectively, for the same period last year. The company reported a second quarter net loss of $22 million, or $0.21 per diluted share, compared with a net loss of $11 million, or $0.11 per diluted share, for the second quarter 2009.

Hypercom Corporation (NYSE: HYC) has scheduled its conference call to discuss second quarter 2010 results for Wednesday, August 4, at 4:30 p.m. ET. The call will be simultaneously webcast.

**************************************************************

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB).